Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) vs Universe Pharmaceuticals INC (UPC)

Shuttle Pharmaceuticals Holdings, Inc. and Universe Pharmaceuticals INC are both Drug Manufacturers Specialty & Generic companies. Universe Pharmaceuticals INC is the larger, with a market value of $23.5M against $15.6M — 1.5× the size. Universe Pharmaceuticals INC has negative trailing earnings, so its P/E is not meaningful; Shuttle Pharmaceuticals Holdings, Inc. trades at 34.7×. Shuttle Pharmaceuticals Holdings, Inc. has the higher net margin (0.00% vs −6.42%) and the lower return on invested capital (−309.8% vs 0.00%). Across the 11 metrics below, Universe Pharmaceuticals INC leads on 7 and Shuttle Pharmaceuticals Holdings, Inc. on 4.

Valuation

Metric SHPH UPC Drug Manufacturers Specialty & Generic median
P/E 34.75 n/m 20.14
P/S n/m n/m 2.25
P/B 0.60 n/m 1.90
Price to free cash flow n/m n/m 16.54
EV/EBITDA n/m 8.52 12.29
EV/Sales n/m (0.24) 2.56
Earnings yield 2.88% (30.74%) (2.99%)
Free cash flow yield (467.78%) 0.00% 0.00%

Profitability

Metric SHPH UPC Drug Manufacturers Specialty & Generic median
Gross margin 0.00% 49.77% 53.94%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% (6.42%) 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (326.36%) 0.00% (0.40%)
Return on assets (126.42%) 0.00% (3.32%)
Return on invested capital (309.75%) 0.00% 0.00%

Growth

Metric SHPH UPC Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) — — 10.01%
EPS growth (last fiscal year) 91.32% 98.71% —
Revenue growth, 5-year CAGR — (10.27%) 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric SHPH UPC Drug Manufacturers Specialty & Generic median
Debt to equity 0.00 0.17 0.05
Current ratio 0.30 4.05 2.31
Net debt to EBITDA 0.03 10.15 0.85

Dividend

Metric SHPH UPC Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio — 0.00 0.00

Size

Metric SHPH UPC Drug Manufacturers Specialty & Generic median
Market cap 15.59m 23.54m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack